Oana Petrenciuc

Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.

Karim Fizazi, Neal D. Shore, Matthew Smith, Teuvo L.J. Tammela et autres

fr, us, fi, de (code pays fourni par la source)

Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial.

Neal D. Shore, Karim Fizazi, Teuvo L.J. Tammela, Murilo Luz et autres

us, fr, fi, br, pe, co, de (code pays fourni par la source)

222P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial

Matthew R. Smith, Neal D. Shore, Teuvo L.J. Tammela, M-A. Le Berre et autres

us, fi, fr, de (code pays fourni par la source)

223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys et autres

fr, us, fi, lt, lv, by, br, ru, de (code pays fourni par la source)

Poster Abstracts

Laurence Krieger, Karim Fizazi, Neal D. Shore, Teuvo Leo Juhani Tammela et autres

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys et autres

fr, fi, us, lt, lv, by, br, ru, de (code pays fourni par la source)

633P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial

Karim Fizazi, Neal D. Shore, Matthew R. Smith, Teuvo L.J. Tammela et autres

fr, us, fi, de (code pays fourni par la source)

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys et autres

fr, us, fi, lt, lv, by, br, ru, de (code pays fourni par la source)

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

Neal D. Shore, Christian Zurth, Robert E. Fricke, Hille Gieschen et autres

us, de, fi, gb, fr (code pays fourni par la source)

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial

Michael J. Morris, Yohann Loriot, Christopher J. Sweeney, Karim Fizazi et autres

us, fr (code pays fourni par la source)

Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program

Oliver Sartor, Nicholas J. Vogelzang, Christopher J. Sweeney, Daniel C. Fernandez et autres

us (code pays fourni par la source)

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

Christopher Parker, Robert E. Coleman, Oliver Sartor, Nicholas J. Vogelzang et autres

gb, us, no, pl, se, sk, de, br (code pays fourni par la source)